期刊
CANCER PREVENTION RESEARCH
卷 3, 期 6, 页码 689-691出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-10-0096
关键词
-
类别
资金
- Cancer Research UK [A10404] Funding Source: Medline
The update of the Study of Tamoxifen and Raloxifene by Vogel et al. (beginning on p. 696 in this issue of the journal) highlights the overall importance of long-term follow-up of cancer prevention trials, which need long follow-up to fully determine agent risks and benefits. Biomarkers (e.g., reduced cervical intraepithelial neoplasia 3 after human papillomavirus vaccination) can provide an early indication of efficacy but almost never replace the cancer end point in determining the ultimate utility of an agent. Long follow-up is also important to fully determine preventive benefit, as illustrated by the tamoxifen trials, where only 60% as many treated women were needed to prevent one cancer at 10 years as at approximately 5 years, the time of the early reports. Cancer Prev Res; 3(6); 689-91. (C) 2010 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据